Cell‐free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls
Cancer · 2024
DOI: 10.1002/cncr.35448 ↗Kurz gefasst
Editorial in der Zeitschrift Cancer, 2024. Verfasst von Helen MacKay und 1 weiteren Autor:innen. Beteiligte Einrichtung: Odette Cancer Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Blanc‐Durand and colleagues present a prospective analysis of cell‐free DNA in patients with recurrent, advanced, or metastatic endometrial cancer, which offers insights into its potential application in molecular classification and the evolving targeted therapy landscape of this disease. More research is needed to validate cell‐free DNA's clinical utility but its potential to guide therapy and improve patient outcomes warrants ongoing exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Odette Cancer Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada.
ORCID-Profile: Helen MacKay, Italo Fernandes
Zitieren
APA
MacKay, H., & Fernandes, I. (2024). Cell‐free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls. Cancer. https://doi.org/10.1002/cncr.35448
Vancouver
MacKay H, Fernandes I. Cell‐free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls. Cancer. 2024. doi:10.1002/cncr.35448
BibTeX
@article{MacKay2024,
author = {MacKay, Helen and Fernandes, Italo},
title = {Cell‐free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35448}
}
EUVIMED